AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16567814 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-enriched bread (31.2 g insoluble fiber/day)
Number of subjects: 17
Study 16567814 — intervention group
Group type: COMPARATOR
Intervention: Control (white bread)
Number of subjects: 17
Study 14530667 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm adhesion barrier
Number of subjects: 1791
Study 14530667 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1791
Study 11029326 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Survanta, 100 mg/kg)
Number of subjects: 19
Study 11029326 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 19
Study 8826172 — intervention group
Group type: EXPERIMENTAL
Intervention: USP-modified lanolin
Number of subjects: 177
Study 8826172 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water compresses
Number of subjects: 177
Study 8826172 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk with air drying
Number of subjects: 177
Study 8826172 — intervention group
Group type: COMPARATOR
Intervention: Control group (education about breastfeeding technique)
Number of subjects: 177
Study 1443354 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cefotaxime (Schedule A)
Number of subjects: 3670
Study 1443354 — intervention group
Group type: COMPARATOR
Intervention: One preoperative dose followed by two postoperative doses of cefotaxime (Schedule B)
Number of subjects: 3670
Study 3914879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pindolol for 24 hours and orally for 48 hours
Number of subjects: 100
Study 3914879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 29862871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined salicylic acid 20% and azelaic acid 20%
Number of subjects: 34
Study 29862871 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid 25%
Number of subjects: 34
Study 29753857 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month retraining interval
Number of subjects: 96
Study 29753857 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month retraining interval
Number of subjects: 96
Study 29753857 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month retraining interval
Number of subjects: 96
Study 29753857 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 96
Study 27189973 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-932481 (γ-secretase modulator)
Number of subjects: 0
Study 25229738 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 Hz PAS
Number of subjects: 0
Study 25229738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz PAS
Number of subjects: 0
Study 25229738 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz burst PAS
Number of subjects: 0
Study 22179955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 22179955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 22179955 — intervention group
Group type: COMPARATOR
Intervention: Any treatment
Number of subjects: 0
Study 20030744 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Pain Detection Device (MPDD)
Number of subjects: 40
Study 20030744 — intervention group
Group type: COMPARATOR
Intervention: Manual Pressure (MP)
Number of subjects: 40
Study 18669425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose sulfate gel
Number of subjects: 1398
Study 18669425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1398
Study 16087822 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate sodium 2.5 mg daily
Number of subjects: 280
Study 16087822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 12169971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Observing Tonometer
Number of subjects: 40
Study 9792935 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (300 IU/kg)
Number of subjects: 40
Study 9792935 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg)
Number of subjects: 40
Study 9792935 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (75 IU/kg)
Number of subjects: 40
Study 9792935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7649702 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer
Number of subjects: 9
Study 7649702 — intervention group
Group type: COMPARATOR
Intervention: Treadmill
Number of subjects: 9
Study 7649702 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant load exercise test
Number of subjects: 9
Study 2614521 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine cream mixed with 500 mg acid mantle cream
Number of subjects: 44
Study 2614521 — intervention group
Group type: COMPARATOR
Intervention: 500 mg acid mantle cream
Number of subjects: 44
Study 641913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined azathioprine and prednisone therapy
Number of subjects: 0
Study 641913 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study 31635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually sequenced specimens
Number of subjects: 0
Study 31635933 — intervention group
Group type: COMPARATOR
Intervention: Pooled specimens (pool sizes of 10, 20, and 40)
Number of subjects: 0
Study 28369332 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro DES
Number of subjects: 124
Study 28369332 — intervention group
Group type: COMPARATOR
Intervention: Nobori DES
Number of subjects: 124
Study 26848888 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent fitness training (1 hour, twice per week for 1 year)
Number of subjects: 26
Study 26848888 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 26
Study 24945241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise group
Number of subjects: 75
Study 24945241 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise group
Number of subjects: 75
Study 22516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulator (GI-Mentor, Symbionix) before hands-on training
Number of subjects: 12
Study 22516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based simulator (GI-Mentor, Symbionix) during hands-on training
Number of subjects: 12
Study 22516665 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 experts)
Number of subjects: 12
Study 22516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training
Number of subjects: 12
Study 20435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical bypass
Number of subjects: 100
Study 20435263 — intervention group
Group type: COMPARATOR
Intervention: Endovascular therapy (angioplasty)
Number of subjects: 100
Study 20435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic bypass grafts
Number of subjects: 100
Study 20435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical bypass after failed angioplasty
Number of subjects: 100
Study 20435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures and costs
Number of subjects: 100
Study 17997890 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cells treatment
Number of subjects: 32
Study 17997890 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (VitB4, batilol, leucogen, inosine, stanozolol)
Number of subjects: 32
Study 15844075 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PnCV)
Number of subjects: 39836
Study 11972943 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN at 128 kbit/s
Number of subjects: 4
Study 11972943 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN at 384 kbit/s
Number of subjects: 4
Study 11972943 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN at 768 kbit/s
Number of subjects: 4
Study 11972943 — intervention group
Group type: COMPARATOR
Intervention: IP transmission
Number of subjects: 4
Study 9633944 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 63
Study 7843010 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser suture lysis following trabeculectomy
Number of subjects: 45
Study 7843010 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without laser suture lysis
Number of subjects: 45
Study 2905287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg prostaglandin E2 in gel
Number of subjects: 40
Study 2905287 — intervention group
Group type: COMPARATOR
Intervention: gel only as placebo
Number of subjects: 40
Study 28353070 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA dietary counselling
Number of subjects: 119
Study 29037226 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection (XNJ) combined with standard care
Number of subjects: 720
Study 29037226 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 720
Study 26226139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/d)
Number of subjects: 80
Study 26226139 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (4 g/d)
Number of subjects: 80
Study 24205023 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of hand actions
Number of subjects: 14
Study 24205023 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of foot actions
Number of subjects: 14
Study 20846874 — intervention group
Group type: EXPERIMENTAL
Intervention: Total arterial revascularization
Number of subjects: 331
Study 20846874 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary surgery
Number of subjects: 331
Study 18427229 — intervention group
Group type: EXPERIMENTAL
Intervention: Active physical therapy (n=51)
Number of subjects: 167
Study 18427229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n=57)
Number of subjects: 167
Study 18427229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (n=59)
Number of subjects: 167
Study 16466838 — intervention group
Group type: EXPERIMENTAL
Intervention: Leftward moving visual stimuli
Number of subjects: 0
Study 16466838 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided moving visual stimuli
Number of subjects: 0
Study 16466838 — intervention group
Group type: COMPARATOR
Intervention: Non-lateralised random moving visual stimuli
Number of subjects: 0
Study 16466838 — intervention group
Group type: COMPARATOR
Intervention: No stimulus condition
Number of subjects: 0
Study 12847998 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation combined with multivitamins, selenium, and magnesium for six months
Number of subjects: 220
Study 12847998 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 220
Study 11304723 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxila 500 mg capsule
Number of subjects: 24
Study 11304723 — intervention group
Group type: COMPARATOR
Intervention: Cefamox 500 mg capsule
Number of subjects: 24
Study 9207344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (VAQTA)
Number of subjects: 70
Study 9207344 — intervention group
Group type: COMPARATOR
Intervention: Immune globulin
Number of subjects: 70
Study 8017402 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer recruitment
Number of subjects: 3788
Study 8017402 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based recruitment
Number of subjects: 3788
Study 8017402 — intervention group
Group type: COMPARATOR
Intervention: Comparison of genders
Number of subjects: 3788
Study 8017402 — intervention group
Group type: COMPARATOR
Intervention: General conclusions
Number of subjects: 3788
Study 3415398 — intervention group
Group type: EXPERIMENTAL
Intervention: Duxil (30 mg almitrine and 10 mg raubasine, 1 tablet b.i.d.)
Number of subjects: 12
Study 3415398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet b.i.d.)
Number of subjects: 12
Study 31916828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 119
Study 31916828 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group for 16 weeks
Number of subjects: 119
Study 31916828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training followed by 4 weeks of deconditioning
Number of subjects: 119
Study 31170944 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention aimed at improving psychosocial working environment, focusing on core job tasks.
Number of subjects: 606
Study 31170944 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention with high or medium degree of implementation.
Number of subjects: 606
Study 31170944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 606
Study 28357460 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 30
Study 28357460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25238492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/d
Number of subjects: 75
Study 25238492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg/day p.o
Number of subjects: 75
Study 25238492 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg p.o when required
Number of subjects: 75
Study 22160300 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental melatonin (1 or 3 mg dosages)
Number of subjects: 24
Study 20949127 — intervention group
Group type: EXPERIMENTAL
Intervention: Random effects models
Number of subjects: 0
Study 20949127 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0
Study 20949127 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-level analyses treating the cluster as the unit of analysis
Number of subjects: 0
Study 20949127 — intervention group
Group type: EXPERIMENTAL
Intervention: Analyses that adjusted for the baseline response
Number of subjects: 0
Study 18422051 — intervention group
Group type: EXPERIMENTAL
Intervention: FHF program (Fostering Healthy Futures)
Number of subjects: 0
Study 16141271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) administration
Number of subjects: 31
Study 16141271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12152004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25 mg daily
Number of subjects: 67
Study 12152004 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 200 mg twice daily
Number of subjects: 67
Study 12152004 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily
Number of subjects: 67
Study 12152004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 9514436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 9514436 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg)
Number of subjects: 9
Study 9514436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7912878 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg manidipine
Number of subjects: 30
Study 7912878 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg manidipine
Number of subjects: 30
Study 7912878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2597953 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin (25% application)
Number of subjects: 37
Study 2597953 — intervention group
Group type: COMPARATOR
Intervention: Scissor excision
Number of subjects: 37
Study 31504336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (quarterly single-dose praziquantel, triple-dose albendazole)
Number of subjects: 1898
Study 31504336 — intervention group
Group type: EXPERIMENTAL
Intervention: Schistosoma mansoni infection
Number of subjects: 1898
Study 31504336 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongyloides infection
Number of subjects: 1898
Study 31504336 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to heavy S. mansoni infection
Number of subjects: 1898
Study 30325449 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of intravenous hydrocortisone followed by 0.5 mg of intravenous dexamethasone every 6 h for 4 doses (STER)
Number of subjects: 43
Study 30325449 — intervention group
Group type: COMPARATOR
Intervention: Surgery without steroids (NOSTER)
Number of subjects: 43
Study 30325449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 28832978 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 59
Study 28832978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg intravenously every 2 weeks plus TRC105 10 mg/kg intravenously every 2 weeks
Number of subjects: 59
Study 28832978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum TGFβ levels below the median (<10.6 ng/mL)
Number of subjects: 59
Study 28832978 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 59
Study 28832978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus TRC105
Number of subjects: 59
Study 25183694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (received written and oral explanations on cardiac rehabilitation benefits and eligibility, and a follow-up telephone call 2 weeks after hospital discharge)
Number of subjects: 1024
Study 25183694 — intervention group
Group type: COMPARATOR
Intervention: Control arm (1-hour seminar to medical staff on the benefits of cardiac rehabilitation)
Number of subjects: 1024
Study 23708389 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal tablets
Number of subjects: 100
Study 23708389 — intervention group
Group type: COMPARATOR
Intervention: Suction curettage
Number of subjects: 100
Study 21564466 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Sedation (DS)
Number of subjects: 520
Study 21564466 — intervention group
Group type: COMPARATOR
Intervention: Moderate Sedation (MS)
Number of subjects: 520
Study 18282319 — intervention group
Group type: EXPERIMENTAL
Intervention: BACS (Brief Assessment of Cognition in Schizophrenia)
Number of subjects: 367
Study 18282319 — intervention group
Group type: EXPERIMENTAL
Intervention: CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness)
Number of subjects: 367
Study 18282319 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, Quetiapine, Risperidone
Number of subjects: 367
Study 16810760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment (n = 42)
Number of subjects: 72
Study 16810760 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 72
Study 16810760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 72
Study 12707571 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 0
Study 10707786 — intervention group
Group type: EXPERIMENTAL
Intervention: PACEBOM
Number of subjects: 459
Study 10707786 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 459
Study 9085392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced screening program including a personalized educational booklet and motivational telephone call and diet-change program including nutrition classes, self-help materials, and computer-generated personalized feedback
Number of subjects: 5042
Study 9085392 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced screening program
Number of subjects: 5042
Study 9085392 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-change program
Number of subjects: 5042
Study 9085392 — intervention group
Group type: COMPARATOR
Intervention: Control group (company-sponsored screening program)
Number of subjects: 5042
Study 1337607 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg
Number of subjects: 13
Study 1337607 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg
Number of subjects: 13
Study 1337607 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 15 mg
Number of subjects: 13
Study 1337607 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (4 mg IV bolus plus 10 mg infused over 2 hr)
Number of subjects: 13
Study 1337607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1337607 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (15 mg)
Number of subjects: 13
Study 2863541 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for 3 months
Number of subjects: 51
Study 2863541 — intervention group
Group type: COMPARATOR
Intervention: Non-warfarin (control)
Number of subjects: 51
Study 29986622 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic overlay tympanoplasty (EOT)
Number of subjects: 70
Study 29986622 — intervention group
Group type: COMPARATOR
Intervention: Microscopic overlay tympanoplasty (MOT)
Number of subjects: 70
Study 26730453 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 534
Study 26730453 — intervention group
Group type: COMPARATOR
Intervention: Placebo/best supportive care (control)
Number of subjects: 534
Study 24452810 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (ABT-888)
Number of subjects: 325
Study 22212956 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 82
Study 22212956 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Not Otherwise Specified BN-type (EDNOS-BN)
Number of subjects: 82
Study 22212956 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 82
Study 19834474 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (aiming at reducing body weight by 10%)
Number of subjects: 20
Study 19834474 — intervention group
Group type: COMPARATOR
Intervention: No intervention (subjects who did not reach the body-weight target)
Number of subjects: 20
Study 18559041 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal
Number of subjects: 30
Study 18559041 — intervention group
Group type: COMPARATOR
Intervention: Ligatures
Number of subjects: 30
Study 16286578 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1235
Study 16286578 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 1235
Study 11939912 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate
Number of subjects: 3045